A randomised placebo controlled crossover trial to evaluate the effects of intrajejunal taurocholic acid on gastrointestinal hormone secretion and glycaemia in response to intrajejunal glucose infusion in healthy humans for the future design of treatments for type 2 diabetes mellitus
Royal Adelaide Hospital
14 participants
Feb 6, 2012
Interventional
Conditions
Summary
The study is designed to evaluate the effects of intrajejunal taurocholic acid on the release of glucagon-like peptide 1 (GLP-1) from the small intestine, and the glycaemic response to concomitant intrajejunal glucose infusion in healthy subjects.
Eligibility
Inclusion Criteria1
- Healthy subjects; Body mass index (BMI) 19 - 30 kg/m2; Haemoglobin > 135 g/L
Exclusion Criteria1
- Medications affecting gut function; Alcohol intake >20g daily or cigarette smoking; Significant gastrointestinal disease or surgery; Impaired liver or renal function; Blood donation within 3 months
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Each healthy volunteer will undergo two treatments (one with taurocholic acid (TCA) 4g and one with control), in double- blind, randomised fashion, separated by 7 days. On each day a small intestinal catheter will be positioned for TCA or control (saline) infusion into the jejunum during both 30 minutes of fasting (2g TCA or saline control) and 120 minutes of concurrent glucose infusion (2g TCA or saline control, together with 60g glucose).
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12612001213831